KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...

Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Semaglutide key ingredients in popular weight loss drugs Ozempic and Wegovy can curb alcohol cravings as per a new study Read ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

A total of nearly 137 million adults, representing more than half of all U.S. adults, are eligible for semaglutide therapy. This ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the ...

The use of diabetes and weight-loss medications like Ozempic or Wegovy—called GLP-1 drugs—has exploded in recent years, with ...

Semaglutide has been on the market since 2017, and it is the active ingredient in the company's top-selling diabetes drug, Ozempic, as well as its weight-loss drug, Wegovy. With semaglutide having a ...

Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...